In today’s briefing:
- Imugene (IMU AU): Got US Patent for Oncolytic Virotherapy- A Crucial Step Forward for US Entry
- Immix Biopharma – IMX-110 interim results in colorectal cancer
- Numinus Wellness, Inc. – A Quarter of Strong Growth; Focus on Cash Burn Reduction
- Teva – ESG Report – Lucror Analytics
Imugene (IMU AU): Got US Patent for Oncolytic Virotherapy- A Crucial Step Forward for US Entry
- Imugene Ltd (IMU AU) got US patent for its oncolytic virotherapy CF33 products, including VAXINIA and CHECKVacc. The patent protects the method of composition and use of CF33 until 2037.
- Imugene has appointed two-decade experienced Dr Ron Weitzman as Interim Chief Medical Officer. Dr Weitzman’s expertise in solid-tumor and hematologic malignancies is of particular interest for Imugene.
- Imugene is actively recruiting patients for its five ongoing clinical trials. The company has a strong balance sheet holding more than A$150 million in cash, providing a runway through 2025.
Immix Biopharma – IMX-110 interim results in colorectal cancer
Immix has shared interim data from the Phase Ib/IIa trial evaluating IMX-110 in combination with tislelizumab for solid tumors. As of the data cut-off (7 July 2023), it was found that three of four participants with metastatic colorectal cancer (mCRC) showed tumor shrinkage and one of four experienced tumor control; all patients had stage IV relapsed/refractory (r/r) mCRC and had received a median eight lines of prior therapy. Dose escalation is proceeding, and dosing of the second cohort of patients in the Phase Ib portion of this study is complete. The higher dose cohort (Cohort 3) of patients with solid tumors is currently being enrolled, aiming to establish the recommended Phase II dose. With no severe adverse events reported to date, and with the early signs of efficacy, we believe these results are encouraging for the clinical development of IMX-110. We anticipate a steady flow of data readouts throughout H223 and FY24.
Numinus Wellness, Inc. – A Quarter of Strong Growth; Focus on Cash Burn Reduction
- Strong sequential revenue growth. Numinus’ fiscal third quarter ended May 31, 2023, delivered revenues of C$6M, a 713% increase from the year ago quarter which was prior to the Novamind acquisition.
- Of greater significance, the company delivered double-digit sequential growth of 12.6%, highlighting the growth track in demand for its clinic and clinical research offerings.
- On this basis, revenues generated across Numinus’ wellness clinics in the US and Canada grew by 5.5% Q/Q, while its clinical research operations (CCR) recorded a sequential revenue surge of 66.7%, as a result of which the division’s share of total revenues climbed to 17% from the prior quarter’s 12%.
Teva – ESG Report – Lucror Analytics
- Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
- We assess Teva’s ESG as “Adequate”, in line with its “Adequate” Environmental and Social scores. The company has “Strong” Governance. Controversies are “Material”, but Disclosure is “Strong”.
- Teva Pharmaceutical Industries Limited is a global company that develops, produces and markets generic medicines and a focused portfolio of speciality medicines.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
